• GE Invests in Manufacturing and Training in Ireland
    Pictured (l to r) are Barry Heavey, Head of Life Sciences at IDA Ireland David Radspinner, General Manager, GE BioParks, Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor, Dominic Carolan, CEO, NIBRT, and Martin Shanahan, CEO, IDA Ireland.

News & Views

GE Invests in Manufacturing and Training in Ireland

Oct 05 2016

Ireland’s Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor TD, announced that GE plans to invest €150 million in a new biopharmaceutical manufacturing campus on Industrial Development Agency (IDA) Ireland’s strategic site at Ringaskiddy, Co. Cork.  GE BioPark Cork will feature Europe’s first KUBio™, prefabricated, bio-manufacturing facilities, comprising  four fully-equipped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, with GE running centralised shared utilities and site services.
 

The BioPark is expected to be home to more than 500 new jobs when fully operational; 400 with the biopharma companies and a further 100 employed directly by GE. The construction phase, subject to planning approvals, is expected to begin by mid- 2017 and create up to 800 construction jobs. The project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
 

To further develop biopharma manufacturing skills and expertise in Ireland, GE and the National Institute for Bioprocessing Research and Training (NIBRT) have also announced plans to create a NIBRT-GE Single-use Centre of Excellence at NIBRT’s Dublin facility. NIBRT expects to train up to 1,500 bioprocessing professionals annually on next-generation biologic manufacturing technologies. These exceptional technologies for biopharma manufacturing will be used in GE BioPark Cork’s manufacturing facilities.
 

Minister Mitchell O’Connor said: "The Biopharma industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of the fastest growing sectors. I am delighted that GE is making a significant investment in Cork.  This is a further testament to our talented workforce.  All investment and jobs created has a positive knock on effect on the wider region.  Over 28,000 people currently work in biopharma and 6,000 of those work in biologics. This subsector is expected to double in the coming years and will provide both a challenge and an opportunity for the industry and training providers to collaborate on promoting the range of career opportunities available.  I welcome GE's commitment to Ireland and wish them every success in the future."
 

Kieran Murphy, CEO, GE Healthcare Life Sciences, GE Healthcare said: “Pharma companies world-wide are racing to respond to patient needs with new life-changing biological medicines and GE is investing in technology and service solutions, as well as industry skills and expertise, to enable them to make and get their products to market more quickly. We are delighted to be investing once again in Ireland, where we have ourselves a long history of manufacturing our own medical imaging products.”


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

Microbiology Society Annual Conference 2024

Apr 08 2024 Edinburgh 2024

analytica 2024

Apr 09 2024 Munich, Germany

ChemBio Finland 2024

Apr 10 2024 Helsinki, Finland

Analytica Anacon India & IndiaLabExpo

Apr 15 2024 Mumbai, India

Analitika Expo 2024

Apr 16 2024 Moscow, Russia

View all events